Sat, Dec 20, 2014, 10:28 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

  • fedupwithwallstreet1110 fedupwithwallstreet1110 Mar 20, 2013 7:53 AM Flag

    Letter about Bloomberg's Dishonesty And Deplorable Journalism

    goog fda letters reza and search for bloomberg

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Here is Part II of Reza's comments on Arena Joins Vivus Finding Obesity Drugs Fizzle on Costs
      And then you compare Belviq to fenfluramine, failing to mention that
      Qsymia has phen in it and then you put heart failure in the same
      sentence which implicitly attributes it to Belviq which is exactly what
      you want to make this a perfect disparaging piece. And you forgot to
      mention that the FDA has determined Belviq doesn't have heart risks to
      warrant a REMS program, and the receptor studies which I guess your
      analyst is too dumb to understand.

      You carry on lying: :"Belviq is indicated for people who have at least
      one coexisting condition such as high blood pressure or Type 2 diabetes."

      That's a flat out lie. A half truth is a lie. You forgot to mention it's also indicated for obese people without a comorbidity.

      In quoting Belviq's efficacy, you forgot to mention Belviq's 11-12%
      responder weight loss statistic because to use a totally meaningless 3%
      number fits your apparent agenda to bash Arena better. Top experts in
      this field know that that 3% number is just that -- meaningless, and the
      responder numbers is what counts.

      Shame on you Bloomberg. You just set a low in bad journalism. This is copied to your top management.

      Sentiment: Hold

    • Here is Part 1 of Reza's comments on Arena Joins Vivus Finding Obesity Drugs Fizzle on Costs
      To: Ryan Flinn, Reg Gale, Andrew Berens

      I often think, reading articles like your today#$%$ piece on Arena,
      that some journalists are worse than prostitutes. Prostitutes still have
      some honors but some journalists seem to be missing a very basic key to
      journalism, which is truthfulness and integrity, and your piece today
      proved me right again.
      I wonder who funded this piece of journalistic disgrace? Who's behind these distortions and negligence?
      "with a third of the population now considered overweight"
      FALSE. two thirds of US population is overweight. You're lying.
      “the drugs are not getting the uptake that people originally thought
      they would,” Andrew Berens, an analyst with Bloomberg Industries,

      This is why people call some analysts Anal-ysts. Is Andrew Berens paid
      by the holders of the 58 million short interest in Arena, or is stupid,
      or is ignorant? How can an analyst comment on a drug that he doesn't
      even know if it's in the market yet or not? How can you assess a drug
      that's not on the market yet to have had good uptake or not? This
      statement needs to be corrected. This is a disparaging lie about Arena's
      drug and market.

      “The overall market has proven to have more hurdles than everyone expected.”

      Based on what? Qsymia's launch alone? Why not admit that most of these
      so called analysts were wrong about this entire space since last year
      and they're still wrong. Qsymia is not Belviq Duh!!!!!!!! Totally
      different mechanism of action. Totally different (and far better) safety
      profile. Your Anal-yst didn't mention that or does he prefer not to
      know it because whoever is paying him might not like it ??

      And then you quote Cory Kasimov -- who's also been wrong about Arena so
      far and will continue to be. There are no signs about Belviq's market
      performance because it's not been in the market.

      Sentiment: Hold

 
ARNA
3.99-0.05(-1.24%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Under Armour, Inc.
NYSEFri, Dec 19, 2014 4:04 PM EST
ImmunoGen, Inc.
NASDAQFri, Dec 19, 2014 4:00 PM EST
Southwestern Energy Co.
NYSEFri, Dec 19, 2014 4:05 PM EST